首页> 外文期刊>Hematological oncology >Follicular dendritic cell sarcoma treated with a variety of chemotherapy
【24h】

Follicular dendritic cell sarcoma treated with a variety of chemotherapy

机译:用各种化疗治疗滤泡性树突细胞肉瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed. The present case had a very poor prognostic disease but survived for a long time with a good performance status because of the multiple chemotherapy regimens, which follow therapeutic strategies for malignant lymphoma and soft tissue sarcoma. As far as we know, this is the first study reporting the indication of bendamustine for FDCS patients.
机译:摘要滤泡树突细胞肉瘤(FDCs)是一种非常罕见的恶性肿瘤,来自滤泡树突细胞。 激进切除是患有局部疾病患者的标准治疗,但尚未确定最佳化疗方案以不切实际的疾病。 我们举报了我们对多功能访问的FDCS患者的经验。 在本案例中,疾病最初仅位于胰腺中,并进行自由基切除。 治疗后开发的多种转移以及观察到预后不良的几个因素。 目前的案例具有非常差的预后疾病,但由于多种化疗方案,良好的性能状况存在很长一段时间,这遵循恶性淋巴瘤和软组织肉瘤的治疗策略。 据我们所知,这是第一项研究报告FDCS患者的蕨类素蛋黄酱的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号